Immuno-Oncology | Specialty

Dr. Garon on Immunotherapy Combinations in NSCLC

April 30th 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non–small cell lung cancer.

FDA Grants Priority Review for Full Approval of Frontline Pembrolizumab Combo in NSCLC

April 30th 2018

The FDA has granted a priority review to a supplemental biologics license application for frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.

Expert Details Immunotherapy Developments in Lung Cancer

April 27th 2018

Charles M. Rudin, MD, PhD, discusses ongoing developments with immunotherapy in patients with non–small cell lung cancer.

Durvalumab/Tremelimumab Misses Endpoint in Phase III NSCLC Study

April 24th 2018

Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival in heavily pretreated patients with locally-advanced or metastatic NSCLC.

HCC: Emerging Therapies

April 24th 2018

Use of Immunotherapy for HCC

April 24th 2018

Clinical Use of Regorafenib in mHCC

April 24th 2018

Treatment of Relapsed/Refractory mHCC

April 24th 2018

First-Line Therapy in Advanced HCC

April 24th 2018

When to Move to Systemic Therapy in HCC

April 24th 2018

HCC: Role of Radiotherapy and Measuring Response

April 24th 2018

When to Use Locoregional Therapies in HCC

April 24th 2018

HCC: Criteria for Resection and Adjuvant Therapy

April 24th 2018

Multidisciplinary Team Approach to Treating HCC

April 24th 2018

Methods for Staging HCC

April 24th 2018

Diagnostic Evaluation of HCC

April 24th 2018

FDA Grants Nivolumab Priority Review for SCLC

April 19th 2018

The FDA has granted a priority review to a supplemental biologics license application for nivolumab (Opdivo) for the treatment of patients with small cell lung cancer with disease progression following 2 or more lines of therapy.

Dr. Eggermont on the Impact of Adjuvant Anti-PD-L1 Agents in Melanoma

April 18th 2018

Alexander M. M. Eggermont, MD, PhD, director general of Gustave Roussy Cancer Campus Grand Paris in Villejuif, France, discusses the impact of adjuvant anti–PD-L1 agents on the treatment landscape of melanoma.

Nivolumab OS Benefit Sustained in Long-Term Follow-Up for SCCHN

April 17th 2018

Treatment with nivolumab reduced the risk of death by 32% compared with investigator’s choice of therapy for patients with metastatic or recurrent squamous cell carcinoma of the head and neck.

Dr. Sharma Discusses Updates from CheckMate-275 in Bladder Cancer

April 17th 2018

Padmanee Sharma, MD, PhD, scientific director, Immunotherapy Platform, The University of Texas MD Anderson Cancer Center, discusses updated findings from the CheckMate-275 trial in bladder cancer during an interview at the 2018 AACR Annual Meeting.